Carregant...
Dealing with hERG liabilities early: diverse approaches to an important goal in drug development
In drug development, early recognition of a potential for blocking the human ether-a-go-go related gene (hERG) channels is perhaps the best way to avoid later disappointment when QT interval prolongation shows up in clinical trials. Knowledge of the hERG blocking liability offers the chance to modif...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Publishing Ltd
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2823348/ https://ncbi.nlm.nih.gov/pubmed/20141517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2009.00265.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|